33,504 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Avanza Fonder AB

Avanza Fonder AB bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, HoldingsChannel.com reports. The firm bought 33,504 shares of the company’s stock, valued at approximately $1,393,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Envestnet Asset Management Inc. increased its position in Moderna by 78.7% during the second quarter. Envestnet Asset Management Inc. now owns 109,733 shares of the company’s stock worth $13,031,000 after buying an additional 48,316 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Moderna by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after acquiring an additional 29,566 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in Moderna by 6.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 4,887 shares of the company’s stock worth $580,000 after purchasing an additional 287 shares during the last quarter. Ieq Capital LLC boosted its position in Moderna by 54.9% during the second quarter. Ieq Capital LLC now owns 15,998 shares of the company’s stock worth $1,900,000 after purchasing an additional 5,668 shares during the period. Finally, Benjamin F. Edwards & Company Inc. grew its holdings in Moderna by 297.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 5,343 shares of the company’s stock valued at $634,000 after purchasing an additional 3,998 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $34.06 on Friday. Moderna, Inc. has a 52-week low of $31.94 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a fifty day moving average price of $40.85 and a two-hundred day moving average price of $66.40. The firm has a market capitalization of $13.11 billion, a P/E ratio of -5.85 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm posted ($1.39) EPS. As a group, analysts anticipate that Moderna, Inc. will post -9.3 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on MRNA shares. Wolfe Research began coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Jefferies Financial Group dropped their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Barclays decreased their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. JPMorgan Chase & Co. dropped their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Finally, Leerink Partners reduced their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday. Four analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $75.58.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. Insiders own 15.20% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.